Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein
about
Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?A new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cellsIntegrating Domain Specific Knowledge and Network Analysis to Predict Drug Sensitivity of Cancer Cell LinesResistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells.Transgenic plants as low-cost platform for chemotherapeutic drugs screeningABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma.Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice.Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancerDasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.Tubulin-targeting agent combination therapies: dosing schedule could matter.The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines.Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.Degradation of P-glycoprotein by pristimerin contributes to overcoming ABCB1-mediated chemotherapeutic drug resistance in vitro.Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivoPharmacokinetics of crizotinib in NSCLC patients.Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon.Co-delivery of Sildenafil (Viagra(®)) and Crizotinib for synergistic and improved anti-tumoral therapy.Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents.Apoptosis sensitization by Euphorbia factor L1 in ABCB1-mediated multidrug resistant K562/ADR cells.Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates.Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3.
P2860
Q28069761-667C2E36-1C84-462E-B9F3-4D7ADA8F2D05Q28541630-F80EE457-C212-43A4-ACB3-0C9BB8D53DC4Q28553930-92A97D11-C36D-4588-B4A9-376AAE514535Q33751197-21E9C59B-F60E-404E-A380-DFA46BE65EFFQ35016736-4054A982-9DCE-46F0-AAA5-82FFB00C6AC2Q35171274-4207701A-0D67-4287-A6AC-EB0157FF6D5FQ35633633-0B31496A-D4CA-4E93-B280-9F9A5DFABFD6Q35860275-6FCBFBF5-E09A-430B-BD10-E68F493AA103Q35978108-EBCCBEC2-ED9F-41D3-8957-A614F37A85B0Q36212765-50F14796-0121-4F5D-A9C4-E33964F5EA21Q36689070-40052883-41DB-4AB4-AA10-EC6215A26D82Q36709217-FA77E742-41AF-44EA-B248-DE8C136D6822Q36887730-6B63D1A4-3F1C-42C5-AC41-8F02D6BE941EQ37697125-36D04F91-A9A2-44FA-B81A-B6A7BA2D0E09Q37707577-E3F7B0A2-6DA9-45AF-8DCB-91A6D08BF66EQ37739472-B6918C52-ED7F-4890-93B6-89B1E31D5074Q38366828-98E665A5-834C-41BB-B7B3-EC8C87AC7B3DQ38718947-DB1366EC-58E4-4C13-9138-2A9DD5437ECCQ38847914-0FA2A312-13B1-46F2-949E-D7FA55C1AADDQ38859977-2EEEB4B9-05CB-4DB3-9488-E3ADF6F87A15Q39016059-2F89D167-4D0B-4D01-AFB2-3F836A738EFAQ39031326-63A97A01-8548-4B4C-90D5-BFCAED134F3FQ39202090-AFF6D5DE-CED8-4598-9FD1-7245DB190291Q42373819-4A6EEA1F-1A2E-46FD-8C2E-3FC552A27064Q45404446-18ECBCE8-24FA-44AD-AD66-F2E40C976C52Q46041746-4D14B098-15C3-40A6-95F3-774151055325Q47100454-08F64D21-532C-4A58-9E46-F5C55899A4ABQ49843204-F5944383-6C50-4112-9396-F47E9230FB30Q49888021-7ECA4DDB-4F74-4200-A9B9-8344FE019C26Q51069180-5DE16FD6-4126-40E0-9536-EDEC5CD8E84F
P2860
Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Crizotinib (PF-02341066) rever ...... the function of P-glycoprotein
@ast
Crizotinib (PF-02341066) rever ...... the function of P-glycoprotein
@en
type
label
Crizotinib (PF-02341066) rever ...... the function of P-glycoprotein
@ast
Crizotinib (PF-02341066) rever ...... the function of P-glycoprotein
@en
prefLabel
Crizotinib (PF-02341066) rever ...... the function of P-glycoprotein
@ast
Crizotinib (PF-02341066) rever ...... the function of P-glycoprotein
@en
P2093
P2860
P1476
Crizotinib (PF-02341066) rever ...... the function of P-glycoprotein
@en
P2093
Chao Cheng
Hong-bing Huang
Kenneth Kin Wah To
Wen-jing Zhou
Xiao-kun Wang
Yong-ju Liang
P2860
P304
P356
10.1111/J.1476-5381.2012.01849.X
P407
P577
2012-07-01T00:00:00Z